Rekvina Labs — 360° view

Rekvina Labs, a company in the Pharmaceuticals industry, reported revenue of ₹0.59 crore and a net loss of ₹0.05 crore for the September 2026 quarter.

Rekvina Labs (BSE: VINRKLB) closed at ₹80.17 on 20 Nov 2026. Its market capitalisation is ₹89 crore.

Share price
₹80.17 (20 Nov 2026)
Market cap
₹89 Cr (20 Nov 2026)
Revenue
₹1 Cr (September 2026 quarter)
Net profit
₹-0 Cr (September 2026 quarter)
ROCE
-333% (FY26)
ROE
% (FY26)
Book value
₹3.14 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹80.17 / ₹6.75 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: VINRKLB

Rekvina Laboratories Limited is engaged in the manufacturing and marketing of pharmaceutical formulations.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.